Answers are grounded in this paper and cite their sources.
Case report demonstrates a durable response to pembrolizumab in recurrent advanced ovarian cancer with a germline MSH6 variant, highlighting the clinical value of genetic evaluation.
This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first‐line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.
No takes yet. Share an insight, caveat, or question.
Yokozawa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: